Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab-dkst
- Development stage
- Approved
- Lead developer
- Viatris
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Trastuzumab-dkst is a biosimilar to trastuzumab, marketed under the brand name Ogivri. It is a humanized IgG1 kappa monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). Trastuzumab-dkst binds to an epitope on the extracellular juxtamembrane domain of HER2, inhibiting its activity and leading to downregulation of downstream survival signaling pathways, cell cycle arrest, and apoptosis. The drug also activates immune-mediated mechanisms such as antibody-dependent cellular cytotoxicity (ADCC). Trastuzumab-dkst is indicated for the treatment of HER2-overexpressing breast cancer (early-stage and metastatic) and HER2-overexpressing metastatic gastric or gastroesophageal junction cancer. It should only be used in patients whose tumors have demonstrated HER2 overexpression[1][3][4][6].
- Brand names
- Ogivri
- Other names
- trastuzumab-dkstbiosimilar trastuzumabOgivri
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab-dkst.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab-dkst.